

# Technology Development Group

# Available Technologies

## Contact Our Team

## **Request Information**

## Gene Editing of Monogenic Disorders in Human Hematopoietic Stem Cells

Tech ID: 29442 / UC Case 2018-372-0

## CONTACT

Permalink

UCLA Technology Development Group ncd@tdg.ucla.edu tel: 310.794.0558.



### INVENTORS

Kohn, Donald B.

### **OTHER INFORMATION**

#### KEYWORDS

hematopoietic stem cell, gene editing,

CRISPR/Cas9, gene therapy

#### CATEGORIZED AS

Medical

- Gene Therapy
- Stem Cell
- Therapeutics

## **RELATED CASES**

2018-372-0

#### SUMMARY

Researchers at the UCLA Department of Microbiology, Immunology & Molecular Genetics have developed novel methods to achieve efficient, precise gene integration and effective expression of cDNA cassettes to express normal versions of genes in hematopoietic stem cells.

#### BACKGROUND

Hematopoietic stem cells (HSCs) have great therapeutic potential because of their ability to both self-renew and differentiate. A small number of genetically modified HSCs could achieve lifelong, corrective reconstitution of the entire hematopoietic system in patients with various hematologic disorders. Many severe primary immune deficiencies (PIDs) are due to defects in lymphoid or hematopoietic cells that can be reconstituted through hematopoietic stem cell transplantation (HSCT). Unlike allogeneic HSCT, gene therapy using autologous HSCs has potential advantages from the absence of graft-versus-host disease and the less intense conditioning and immune suppression needed. Lentiviruses were the most widely used viral vectors to safely and effectively deliver a transgene of interest into HSCs for gene therapy. However, even though lentiviruses have been improved with lower risk of genotoxicity and increased safety compared with gammaretroviruses, lentivirus-based HSC gene therapy can still theoretically result in toxicity due to dysregulated transgene expression or residual genotoxicity.

HSC-targeted gene editing technologies using engineered nucleases such as CRISPR/Cas9, allow for the site-specific correction of diseasecausing mutations and have shown promising clinical benefits in multiple diseases. The ability to correct specific disease-causing mutations, rather than simply deliver a normal gene, extends the potential applications of gene therapy to dominant disorders in addition to those resulting from simple loss-of-function mutations.

#### **INNOVATION**

Researchers at UCLA have defined optimal design features of homologous donors (cDNA expression cassettes and homology arms) and CRISPR/Cas9 target sites for more efficient, precise gene integration, and effective expression of cDNA cassettes to express normal versions of genes in hematopoietic stem cells. The optimization will help minimize both targeted-re-cutting by nuclease and illegitimate recombination, and allow precise control of transgene expression to the highest level.

#### **APPLICATIONS**

Gene therapy of hemoglobinopathies (*i.e.*, sickle cell disease, beta-thalassemia)

Gene therapy of immune deficiencies (*i.e.*, different genetic forms of severe combined immunodeficiency, X-linked Hyper IgM Syndrome, X-linked agammaglobulinemia, common variable immune deficiency, chronic granulomatous disease, Wiskott–Aldrich syndrome, hemophagocytic lymphohistiocytosis, leukocyte adhesion deficiency)

▶ Gene therapy of storage and metabolic diseases (*i.e.*, Gaucher, Hurler's, Hunters, San Filipo, etc.)

#### **ADVANTAGES**

More efficient and effective gene editing

Better expression of inserted transgenes

#### STATE OF DEVELOPMENT

The method has been tested in vitro.

#### **PATENT STATUS**

Country	Туре	Number	Dated	Case
United States Of America	Published Application	20210379105	12/09/2021	2018-372

Additional Patent Pending

#### **RELATED MATERIALS**

C.Y. Kuo and D. B. Kohn, Gene Therapy for Primary Immune Deficiency Diseases, Clinical Immunology (Fifth Edition), 2019.

▶ D. B. Kohn and C.Y. Kuo, New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing, Journal of Allergy and Clinical Immunology, 2017.

C.Y. Kuo, J. D. Long, B. Campo-Fernandez, S. de Oliviera, A. R. Cooper, Z. Romero, M. D. Hoban, A.V. Joglekar, G. Lill, M. L. Kaufman, S. Fitz-Gibbon, X. Wang, R. P. Hollis, and D. B. Kohn, Targeted Gene Insertion for the Treatment of X-Linked Hyper-IgM Syndrome, Cell Reports, In Press.

### ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Augmentations to Lentiviral Vectors to Increase Expression
- ▶ Improvement To Retroviral Vectors Containing The Human Ubiquitin C Promoter
- ▶ Generation Of Minimal Enhancer Elements Using Massively Parallel Reporter Assays
- Optimized Lentiviral Vector for Stem Cell Gene Therapy of Hemoglobinopathies
- Transient Expression Of BCL-2 To Ameliorate Cytotoxicity Of Gene Modification Reagents In Stem Cells
- ▶ Fusion Protein For Anti-Cd19 Chimeric Antigen Receptor Detection

## Gateway to Innovation, Research and Entrepreneurship

### UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095 https://tdg.ucla.edu

 $\ensuremath{\textcircled{\text{C}}}$  2018 - 2021, The Regents of the University of California Terms of use **Privacy Notice** 



Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu